BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy

OBJECTIVE: In this study, we aimed to investigate the predictive effect of BRCA1, STMN1, MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC). METHODS: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mingxing, Li, Wanjun, Xing, Xuemei, Zhang, Dan, Lei, Jie, Li, Guoyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655245/
https://www.ncbi.nlm.nih.gov/pubmed/29113350
http://dx.doi.org/10.18632/oncotarget.20715
_version_ 1783273495801626624
author Wang, Mingxing
Li, Wanjun
Xing, Xuemei
Zhang, Dan
Lei, Jie
Li, Guoyin
author_facet Wang, Mingxing
Li, Wanjun
Xing, Xuemei
Zhang, Dan
Lei, Jie
Li, Guoyin
author_sort Wang, Mingxing
collection PubMed
description OBJECTIVE: In this study, we aimed to investigate the predictive effect of BRCA1, STMN1, MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC). METHODS: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of BRCA1, STMN1, MAPT and TUBB3 were determined. Survival time of the patients with NSCLC was also calculated. RESULTS: High expression of BRCA1 or low expression of STMN1 was associated with a better prognosis in NSCLC patients (p<0.01). In contrast, the expression of MAPT and TUBB3 were not closely related with the prognosis of NSCLC patients(p>0.05). Furthermore, patients with high expression of BRCA1 and low expression of STMN1 have lived longer (p<0.01). CONCLUSION: BRCA1 and STMN1 were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy.
format Online
Article
Text
id pubmed-5655245
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-56552452017-11-06 BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy Wang, Mingxing Li, Wanjun Xing, Xuemei Zhang, Dan Lei, Jie Li, Guoyin Oncotarget Research Paper OBJECTIVE: In this study, we aimed to investigate the predictive effect of BRCA1, STMN1, MAPT and TUBB3 on the prognosis of patients with non-small cell lung cancer (NSCLC). METHODS: Seventy NSCLC patients who received platinum-based chemotherapy from June 2009 to July 2011 were enrolled. The protein and mRNA levels of BRCA1, STMN1, MAPT and TUBB3 were determined. Survival time of the patients with NSCLC was also calculated. RESULTS: High expression of BRCA1 or low expression of STMN1 was associated with a better prognosis in NSCLC patients (p<0.01). In contrast, the expression of MAPT and TUBB3 were not closely related with the prognosis of NSCLC patients(p>0.05). Furthermore, patients with high expression of BRCA1 and low expression of STMN1 have lived longer (p<0.01). CONCLUSION: BRCA1 and STMN1 were independently predictors for prognosis of NSCLCs which received cisplatin-based adjuvant chemotherapy. Impact Journals LLC 2017-09-08 /pmc/articles/PMC5655245/ /pubmed/29113350 http://dx.doi.org/10.18632/oncotarget.20715 Text en Copyright: © 2017 Wang et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research Paper
Wang, Mingxing
Li, Wanjun
Xing, Xuemei
Zhang, Dan
Lei, Jie
Li, Guoyin
BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
title BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
title_full BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
title_fullStr BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
title_full_unstemmed BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
title_short BRCA1 and STMN1 as prognostic markers in NSCLCs who received cisplatin-based adjuvant chemotherapy
title_sort brca1 and stmn1 as prognostic markers in nsclcs who received cisplatin-based adjuvant chemotherapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655245/
https://www.ncbi.nlm.nih.gov/pubmed/29113350
http://dx.doi.org/10.18632/oncotarget.20715
work_keys_str_mv AT wangmingxing brca1andstmn1asprognosticmarkersinnsclcswhoreceivedcisplatinbasedadjuvantchemotherapy
AT liwanjun brca1andstmn1asprognosticmarkersinnsclcswhoreceivedcisplatinbasedadjuvantchemotherapy
AT xingxuemei brca1andstmn1asprognosticmarkersinnsclcswhoreceivedcisplatinbasedadjuvantchemotherapy
AT zhangdan brca1andstmn1asprognosticmarkersinnsclcswhoreceivedcisplatinbasedadjuvantchemotherapy
AT leijie brca1andstmn1asprognosticmarkersinnsclcswhoreceivedcisplatinbasedadjuvantchemotherapy
AT liguoyin brca1andstmn1asprognosticmarkersinnsclcswhoreceivedcisplatinbasedadjuvantchemotherapy

Ejemplares similares